+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      LHRH Injected into the Medial Preoptic Area Potentiates LH Secretion in Ovariectomized Estrogen-Primed and Proestrous Rats

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          To determine if luteinizing hormone releasing hormone (LHRH) might act within the central nervous system to modulate its own secretion, microinjection of LHRH into the medial preoptic area (MPO) was performed at 13:00 h in both the ovariectomized estrogen-primed and proestrous rat, and the effects on the afternoon rise in the serum concentration of luteinizing hormone (LH) were studied. Microinjection of 5 ng LHRH into the MPO in the ovariectomized estrogen-primed rat resulted in a significant increase in serum LH from 16:00 to 19:00 h compared to the value in the saline-injected rat, whereas the injection at a dose of 2 ng did not induce a significant change. The injection of 5 ng LHRH into the third ventricle in the ovariectomized estrogen-primed rat induced a transient increase in serum LH immediately after the injection, followed by recovery to the preinjection concentration by 1 h, indicating that the potentiating effect of 5 ng LHRH in the MPO was not due to the LHRH leaked into the third ventricle. Finally, microinjection of 5 ng LHRH in the proestrous rat induced an early increase in serum LH, resulting in an advancement of the peak of the afternoon rise by 1 h. It is suggested that LHRH secreted in the MPO may, directly or indirectly, stimulate its own secretion in the median eminence to produce the surge of LH secretion.

          Related collections

          Author and article information

          S. Karger AG
          02 April 2008
          : 50
          : 4
          : 421-426
          Department of Physiology, Yokohama City University School of Medicine, Yokohama, Japan
          125258 Neuroendocrinology 1989;50:421–426
          © 1989 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Original Paper


          Comment on this article